MEDP — Medpace Holdings Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $653.09
- YTD price return
- +16.28%
- YTD total return
- +16.28%
- Market cap
- 18.3B
- Enterprise value
- 17.7B
- Shares outstanding
- 28M
- 52W low
- $373.00
- 52W high
- $693.97
- From 52W high
- -5.89%
- From 52W low
- +75.09%
- 52W range
- 87%$373–$694
- Beta
- 1.14
Volume
- Rel volume
- 0.62×
- 30D volume
- 282.8K
- 30D $ vol
- 183.2M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$14.4M
- Insider net 3M
- −$174.9M
- Insider net 1Y
- −$244.7M
Form 4 transactions by trade date, as filed; latest on file 2026-10-29.
Fundamentals
- Sales (ttm)
- 2.8B
- Sales/share
- $101.47
- EPS (ttm)
- $18.03
- FCF (ttm)
- 667.6M
- FCF/share
- $23.87
- Book value/share
- $20.91
- Net margin
- 18.24%
- ROE
- 88.53%
- ROA
- 22.49%
- Current ratio
- 0.83
Growth (CAGR, ttm) · 10Y
- Sales
- +20.37%+16.79%+21.02%+21.61%
- Net income
- +19.60%+23.75%+23.17%+59.48%
- FCF
- -1.35%+20.90%+19.76%+24.61%
- Shares
- -0.70%-3.04%-4.89%-3.69%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +26.03%+28.26%+30.13%+65.09%
- Sales/share
- +21.22%+20.45%+27.24%+26.39%
- FCF/share
- -0.66%+24.68%+25.92%+29.51%
- Book value/share
- +100.70%+10.86%-3.50%+3.38%
- Price
- +11.50%+33.57%+23.49%+33.66%
- Total return
- +11.50%+33.57%+23.49%+33.66%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 36.2×
- P/OI (ttm)
- 30.1×
- Fwd P/E
- 32.9×
- P/S (ttm)
- 6.4×
- P/B (mrq)
- 31.2×
- P/FCF (ttm)
- 27.4×
- EV/EBITDA (fy)
- 28.0×
- EV/Sales (ttm)
- 6.2×
- FCF yield (ttm)
- 3.65%
- Buyback yield (realized, 1y)
- 0.70%
- Shareholder yield (realized, 1y)
- 0.70%
- Buyback yield (cash, ttm)
- 1.61%
- Shareholder yield (cash, ttm)
- 1.61%
Vs own 10Y history
- P/E
- 65th
- P/OI
- 77th
- P/S
- 91st
- P/B
- 91st
- P/FCF
- 95th
Bar = where today’s multiple sits in MEDP’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +26.2%10Y CAGR +38.5%YoY +16.7%EPS (diluted)
5Y CAGR +31.8%10Y n/mYoY +25.4%Free cash flow
5Y CAGR +24.6%10Y CAGR +24.0%YoY −16.6%TTM: operating cash flow $723M, capex −$55.4M
Q3 2026: operating cash flow $216.6M, capex −$20.2M
Shares (diluted)
5Y −21.7%10Y −5.8%YoY −1.5%Net income
5Y CAGR +25.4%10Y n/mYoY +23.7%About Medpace Holdings#
Data provided bySource: Twelve DataMedpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.
Cincinnati, OH·6,600 employees·Diagnostics & Research·medpace.com·As of Oct 28, 2026
Recent filings#
- Oct 29Insider sale · EWALD STEPHEN P (General Counsel & Corp. Secy.) sold 1,245 shares for $859K at $690.00
- Oct 27Insider sale · BURWIG SUSAN E (Exec. VP, Operations) sold 27,500 shares for $18.0M on 3 days since Jul 28
- Oct 21Earnings · Earnings release — EPS $4.84 vs $4.45 est. (+8.8%); revenue $716.0M (+9% y/y) 1.3%
- Sep 30Insider sale · Troendle August J. (President & CEO · Director · 10% owner) sold 307,959 shares for $190.9M on 24 days since Jul 27
- Aug 26Insider sale · Kraft Robert O. (Director) sold 3,858 shares for $2.4M at $617.81
ETFs holding MEDP#
22 of the 193 ETFs ChartRow carries live hold MEDP. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.0% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
